Alzheimers Dement: Suvorexant improves sleep in people with suspected AD dementia and insomnia

A randomized, double-blind clinical trial evaluated the clinical condition of the treatment of mild and moderate suspected Alzheimer's disease (AD) insomnia by the rexin-subject antagonist suvorexant, the results of which were published online in Alzheimers Dement.
study, which lasted 4 weeks, included patients who met the clinical diagnostic criteria for suspected AD dementia and insomnia, using suvorexant 10 mg (which can be increased to 20 mg depending on the clinical response) or a placebo treatment.
in the sleep lab by using a night-time multi-guide sleep map to assess sleep.
end point is the change in the relative baseline of total sleep time (TST) from the 4-week multi-guide sleep graph.
results, the trial was completed in 285 random participants (Suvorexant, N, N, 142; placebo, N, 143), and 277 (97%) (suvorexant, N, 136; placebo, N, 141).
in week 4, the suvorexant group TST improved to 73 minutes and the placebo group for 45 minutes;
4.2 percent of patients treated with suvorexant and 1.4 percent of placebo patients reported drowsiness.
, sudorexant improved TST in patients with suspected AD dementia and insomnia.
。